ASK also induces molecular effects which result detrimental to metastatic potential, such as downregulation of N-cadherin, P-cadherin (Figure 5B) and MMP9 (Figure 7E), further strengthening the potential of this strategy for RCC therapy. Here, CDH3 is linked to renal cell carcinoma.